Preoperative treatment with elacestrant is associated with relevant biological and molecular responses. Read More ›

Ribociclib plus ET shows promising efficacy as maintenance therapy in patients with HR-positive/HER2-negative metastatic breast cancer. Read More ›

Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer. Read More ›

No significant differences in PFS were found between abemaciclib, palbociclib, and ribociclib in a real-world setting. Read More ›

Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer. Read More ›

Post-progression targeted therapy after ribociclib found to result in increased duration of therapy. Read More ›

Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date. Read More ›

Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes. Read More ›

Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups. Read More ›